MedTrace Logo

Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy

NCT02735213 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2019-07-18

No results posted yet for this study

Summary

The purpose of this study is to observe whether micropulse laser (MPL) is noninferiority to traditional laser therapy in central serous chorioretinopathy.

Conditions

  • Central Serous Choroidopathy

Interventions

DEVICE

577-MPL

9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250\~400 milliWatts of power(50% threshold power),150\~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.

DEVICE

TLT

contimuous wave,100um spot size, 0.05 seconds duration, 55\~60 milliwatts of power, 18\~27 spots,the laser area is the corresponding leakage on mid-phase FA.

Sponsors & Collaborators

  • The Eye Hospital of Wenzhou Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02735213 on ClinicalTrials.gov